Can-Fite BioPharma (NYSE:CANF) Receives Buy Rating from D. Boral Capital

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other equities research analysts have also issued reports on CANF. StockNews.com lowered Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

CANF stock opened at $1.59 on Thursday. Can-Fite BioPharma has a 1 year low of $1.29 and a 1 year high of $4.69. The stock’s 50 day moving average price is $2.20 and its 200 day moving average price is $2.51. The firm has a market cap of $5.63 million, a P/E ratio of -0.89 and a beta of 1.32.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.